Future of Therapy for Inborn Errors of Immunity.

Authors:
Perez E.

Journal:
Clin Rev Allergy Immunol

Publication Year: 2022

DOI:
10.1007/s12016-021-08916-8

PMCID:
PMC8753954

PMID:
35020169

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Clin Rev Allergy Immunol

Abbreviation: Clin Rev Allergy Immunol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Autoinflammatory Keratinization Diseases-The Concept, Pathophysiology, and Clinical Implications.
Blicharz L; Czuwara J; Rudnicka L and 1 more (2023) - Transparency Score: 2/6
Environmental Risk Factors, Protective Factors, and Biomarkers for Allergic Rhinitis: A Systematic …
Xu X; Liu X; Li J and 5 more (2023) - Transparency Score: 4/6
Food Allergy Labeling Laws: International Guidelines for Residents and Travelers.
Chang F; Eng L; Chang C. (2023) - Transparency Score: 2/6
Advanced Imaging Supports the Mechanistic Role of Autoimmunity and Plaque Rupture in COVID-19 Heart…
Laino ME; Ammirabile A; Motta F and 7 more (2022) - Transparency Score: 2/6
A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification System…
Lazzaroni MG; Piantoni S; Angeli F and 3 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics ApprovalNot applicable. Consent to ParticipateNot applicable. Conflict of Interest/Competing InterestConsultancy work for Takeda, Grifols, CSL Behring; Speaker bureau for Takeda, Genentech, CSL Behring. Conflict of Interest/Competing Interest Consultancy work for Takeda, Grifols, CSL Behring; Speaker bureau for Takeda, Genentech, CSL Behring."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025